References
- Breslau N, Rasmussen BK. The impact of migraine: epidemiology, risk factors and comorbidities. Neurology56\(Suppl. 1), 4–12 (2001).
- Goadsby PJ, Lipton RB, Ferarri MD. Migraine — current understanding and treatment. N Engl. I Med. 346, 257–270 (2002).
- Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study. Headache 41, 646–657 (2001).
- Ferrari MD. The economic burden of migraine to society. PharmacoEconomics13, 667–676 (1998).
- Lipton RB, Goadsby PJ, Sawyer JPC et al Migraine: diagnosis and assessment of disability. Rev Contemp. Pharmacother. 11, 63–73 (2000).
- Dowson AJ, Lipscombe S, Sender J, T, Watson D. New guidelines for the management of migraine in primary care. Curt: /1/ed. Res Opin. 18(7), 414–439 (2002).
- Dowson AJ, Sender J, Lipscombe S et al. Establishing principles for migraine management in primary care. Int. J. Gun. Pract. 57(6), 493–507 (2003).
- ••Key recent consensus migrainemanagement guidelines.
- Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1viD agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
- •The largest and most comprehensive of the triptan meta-analyses.
- Fox AW. Comparative tolerability of oral 5-HT1viD agonists. Headache 40, 521–527 (2000).
- Bou J, Domenech T, Puig J, Heredia A et al Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur. Pharmacol 410,33–41 (2000).
- ••Key pharmacological studywith almotriptan.
- Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 21(8), 804–812 (2001).
- Gras J, Bou J, Llenas J, Fernandez AG, Palacios JM. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eurr. j Pharmacol 410(1), 43–51 (2000).
- Gras J, Cardelus I, Llenas J, Palacios JM. Cardiovascular safety of almotriptan, a new indolic derivative for the treatment of migraine. Eur.j Pharmacol 410(1), 53–59 (2000).
- Fleishaker JC, McEnroe JD, Azle NE, Francom SF, Carel BJ. Cardiovascular effects of almotriptan in treated hypertensive patients. Clin. Pharmacol Then 71(3), 169–175 (2002).
- Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs60, 1259–1287 (2000).
- Garcia E, Cabarrocas X, Jansat JM. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5HT1B/ID agonist, in healthy volunteers. I-kadache 38, 376 (1998).
- Cabarrocas X, Jansat JM, Ferrer P, Luria X. Pharmacokinetics and absorption of oral almotriptan during and outside a migraine attack. Cephalalgia l9, 417 (1999).
- Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. Absolute bioavailability, pharmacokinetics and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J. Gun. Pharmacol 42(12), 1303–1310 (1998).
- Gras J, Llupia J, Llenas J, Palacios JM. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics. Arzneimittelforschung 51, 726–732 (2001).
- Salva M, Jansat JM, Martinez-Tobed A, Palacios JM. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug. Metab. Dispos. 31, 404–411 (2003).
- Cabarrocas X, Fernandez FJ, Popescu G, Jansat JM, Molz K, Ferrer P The pharmacokinetics and tolerability of almotriptan in renal impairment. Headache 39, 346 (1999).
- Cabarrocas X, Warrington SJ, Jansat JM, Zayas JM, Boyce M, Ferrer P Pharmacokinetics and tolerability of oral almotriptan in the elderly. Cephalalgia 19, 363 (1999).
- Gras J, Llenas J, Jansat JM, Jauregui J, Cabarrocas X, Palacios JM. Almotriptan, a new antimigraine agent: a review. CNS Drug Rev. 8, 217–234 (1999).
- Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin. Pharmacol Therapy67, 498–503 (2000).
- Fleishaker JC, Ryan KK, Jansat JM et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. BE J. Clin Pharmacol 51, 437–441 (2001).
- Fleishaker JC, Ryan KK, Carel BJ, Azle NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.' Gun. Pharmacol 41, 217–223 (2001).
- Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan and propranolol in healthy volunteers. Cephalalgia 2l, 61–65 (2001).
- Cabarrocas X, Salva M. Almotriptan has no pharmacokineticipharmacodynamic interaction with ethanol. Cephalalgia 22(7), 605 (2002).
- Cabarrocas X, Macher J-P Lack of pharmacokinetic interaction between almotriptan and oral contraceptives: a double-blind, placebo-controlled, crossover study in healthy female volunteers. Cephalalgia 23(7), 716 (2003).
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgla 8\(Suppl. 7), 1–92 (1988).
- Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neural. 31, 295–299 (1991).
- Pascual J. Almotriptan: a novel 5-HT1B/ID agonist for the symptomatic relief of migraine. Exp. Rev Neurotherapeutics1(1), 20–7 (2001).
- Boyce M, Dunn K, Warrington S. Haemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. Catrliovasc. Pharmacol 37, 280–289 (2001).
- DahlOf C, Tfelt-Hansen P, Massiou H, Fazekas A. Dose-finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology57, 1811–1817 (2001).
- ••The definitive dose-finding studywith almotriptan.
- Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomised, double-blind, placebo-controlled study. Cephalalgia 20, 588–596 (2000).
- ••A key Phase III study with almotriptan.
- Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 22, 453–461 (2002). A key Phase In study with almotriptan.
- Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan versus oral sumatriptan in the abortive treatment of migraine: a double-blind, randomised, parallel-group, optimum-dose comparison. Arch. Neural. 58, 944–950 (2001).
- ••A key Phase III study with almotriptan.
- Mathew N. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine attacks. Headache 42, 32–40 (2002).
- Pascual J, Falk RM, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neural. 45, 206–213 (2001).
- Pascual J, Lainez JM, Leira R et al Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study. Neurologla 18(1), 7–17 (2003).
- Pascual J. Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2001 observational study. Headache 43, 525 (2002).
- Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/ID agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22, 633–658 (2003).
- Dahl& CG, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 42, 99–113 (2002).
- Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache 42, 21–27 (2002).
- Mathew NT Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. Clin. Ther 24, 520–529 (2002).
- Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. Headache 42 (Suppl. 1), 26–31 (2002).
- Cady RK, Lipton RB, Hall C et al Treatment of mild headache in disabled migraine sufferers: results of the Spectrum study. Headache 40, 792–797 (2000).
- •Landmark study that has demonstrated that triptans are most effective when used early in the migraine attack, when the headache is mild in intensity
- Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 42,28–31 (2002).
- Dowson AJ, Massiou H, Lanez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 h of migraine onset. Headache (2004) (In Press).
- Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache41,449–455 (2001).
- Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Gun. Ther. 23,127–145 (2001).
- Mayo KW, Osterhaus JT. Health outcomes evaluations: estimating the impact of almotriptan in managed care settings. Am.J Manag. Care 8, S85—S93 (2002) .
- Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 42 (Suppl. 1), 38–43 (2002) .
- Williams P, Reeder CE. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Gun. Ther. 25, 2903–2919 (2003).
Website
- Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. www.neurology.org/cgi/reprint/55/6/754.pdf (Accessed April 2004)